Translated title of the contribution: Terazosin in the benign prostatic hyperplasia therapy

M. Andres, O. De Cobelli, L. Carmignani, R. Musci, E. Kocjancic, M. Panizzutti, F. Rocco

Research output: Contribution to journalArticlepeer-review


Benign prostatic hypertrophy provokes clinical manifestations correlated on one hand to a static obstructive component, due to the increase in glandular size, and on the other hand to a dynamic component, controlled by the alpha adrenergic autonomic system which gives the smooth muscular tonus of the prostatic adenoma. The alpha adrenergic receptor block reduces the dynamic component, improves the clinical and urodynamic parameters determined by the infrabladder obstruction in patients with BPH. The selective alpha 1, long acting antagonists especially, such as terazosin, offer a safe and efficient therapy for selected patients suffering from BPH. They also have the indiscutable benefit of monoadministration. In this study the basic concepts of BPH treatment with terazosin are discussed.

Translated title of the contributionTerazosin in the benign prostatic hyperplasia therapy
Original languageItalian
Pages (from-to)37-39
Number of pages3
JournalArchivio Italiano di Urologia e Andrologia
Issue number1
Publication statusPublished - 1995

ASJC Scopus subject areas

  • Nephrology
  • Urology


Dive into the research topics of 'Terazosin in the benign prostatic hyperplasia therapy'. Together they form a unique fingerprint.

Cite this